STAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill
Why it matters: A pill could bring effective weight‑loss therapy to millions who avoid injections.
- Structure Therapeutics unveiled a mid‑stage GLP‑1 pill that cut participants’ weight by up to 20% (STAT+).
- Phase 2b trial results exceeded expectations, prompting the company to fast‑track a Phase 3 study (company press release).
- Analysts note the oral route could dramatically broaden access compared with current injectable drugs (industry commentary).
- Patients with obesity may soon have a convenient, non‑injectable option, expanding treatment uptake (expert opinion).
Structure Therapeutics’ oral GLP‑1 drug delivered a 15‑20% average weight loss in its mid‑stage trial, spurring a rapid move to Phase 3 and positioning a pill as a potential game‑changer to injectable obesity treatments.
